Pharmacogenetic Testing in Treatment-resistant Panic Disorder: a Preliminary Analysis
Commercial pharmacogenetic testing failed to predict negative treatment outcome in most patients with PD. The association between treatment-resistance in PD and the genes CYP2C19, MTHFR and ABCB1 deserves further study.
Authors
- Antônio Egídio Nardi (ORCID: https://orcid.org/0000-0002-2152-4669)
- Marcos Fidry (ORCID: https://orcid.org/0000-0002-8157-8562)
- Morena Mourao Zugliani (ORCID: https://orcid.org/0000-0003-2370-5495)
- Mariana Costa do Cabo (ORCID: https://orcid.org/0000-0003-4279-2088)
- Clara Gitahy Falcão Faria (ORCID: https://orcid.org/0000-0002-1290-2349)
- Rafael C. Freire (ORCID: https://orcid.org/0000-0003-3875-4601)
- Renan Machado Martins
- María Ángeles Ruiz Gómez
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Queen's University (CA)
- Kingston General Hospital (CA)
- Kingston Health Sciences Centre (CA)
Publication Details
- Journal
- Clinical Practice and Epidemiology in Mental Health
- Published
- 2024-12-03
- DOI
- https://doi.org/10.2174/0117450179337258241031035148
- Citations
- 1
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Ministério da Ciência, Tecnologia e Inovação
- Conselho Nacional de Desenvolvimento Científico e Tecnológico